Placebo responses vary by route of administration in migraine prevention trials. What does this mean?

J Med Econ. 2024 Jan-Dec;27(1):442-444. doi: 10.1080/13696998.2024.2323900. Epub 2024 Mar 12.

Authors

Christina I Deligianni^{1

2}, Paolo Martelletti³, Dimos D Mitsikostas²

Affiliations

¹ Neurology Department, Athens Naval Hospital, Athens, Greece.
² 1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian Universtiy of Athens, Athens, Greece.
³ School of Health Sciences, Unitelma Sapienza University of Rome, Rome, Italy.

PMID: 38425286
DOI: 10.1080/13696998.2024.2323900

No abstract available

Publication types

Editorial

MeSH terms

Double-Blind Method
Humans
Migraine Disorders* / drug therapy
Research Design
Treatment Outcome